CLDX
Celldex Therapeutics, Inc.
Nasdaq In Vitro & In Vivo Diagnostic Substances Large accelerated filer

Key Financials

Operating Income
$-287367000
↓ 47.3%
Net Income
$-258757000
↓ 63.9%
EPS (Diluted)
$-3.90
↓ 59.2%
Total Assets
$583.0M
↓ 26.4%
Revenue
$1.5M
↓ 78.0%
Cash & Equivalents
$28.9M
↑ 1.8%
Total Liabilities
$55.8M
↑ 23.1%
Shareholders' Equity
$527.2M
↓ 29.4%

Recent SEC Filings

Form Type Filed Date Link
SCHEDULE 13G/A 8/14/2026 View on SEC
SCHEDULE 13G 8/14/2026 View on SEC
10-Q 8/6/2026 View on SEC
8-K 8/6/2026 View on SEC
8-K 7/15/2026 View on SEC
4 6/29/2026 View on SEC
4 6/29/2026 View on SEC
4 6/29/2026 View on SEC
4 6/29/2026 View on SEC
4 6/29/2026 View on SEC

Company Information

Field Value
Ticker CLDX
Company Name Celldex Therapeutics, Inc.
CIK 744218
Sector In Vitro & In Vivo Diagnostic Substances
Industry Large accelerated filer
Exchange Nasdaq
SIC Code 2835
SIC Description In Vitro & In Vivo Diagnostic Substances
Entity Type operating
Fiscal Year End 1231
State of Incorporation DE
Phone 908-200-7500